The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1581
ISSUE 1581
September 23, 2019
Issue 1581
- Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia
- Glucagon Nasal Powder (Baqsimi) for Severe Hypoglycemia
- Duaklir Pressair: Another LAMA/LABA Inhaler for COPD
- Qmiiz ODT - An Orally Disintegrating Meloxicam Tablet
- In Brief: Ezallor Sprinkle - A New Formulation of Rosuvastatin
- Expanded Table: Statins (online only)
| Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue. |
Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia
September 23, 2019 (Issue: 1581)
Lefamulin (Xenleta – Nabriva), a semisynthetic
pleuromutilin antibiotic, has been approved by the
FDA for IV and oral treatment of community-acquired
bacterial pneumonia (CABP) in adults. It is the first
systemic pleuromutilin antibiotic to be approved in the
US; retapamulin (Altabax), a 1% topical ointment for
treatment of impetigo, was approved in 2007.
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1581
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
